North America Cancer Immunotherapy Market Insights Forecasts to 2033

• The Market Size is Growing at a CAGR of 11.7% from 2023 to 2033
• The North America Cancer Immunotherapy Market Size is Expected to Hold a Significant Share by 2033

The North America Cancer Immunotherapy Market Size is Anticipated to Hold a Significant Share by 2033, growing at a CAGR of 11.7% from 2023 to 2033.

Market Overview

Cancer immunotherapy, also known as immuno-oncology, is a type of treatment that uses the immune system to recognize, target, and eliminate cancer cells. Unlike traditional cancer treatments like chemotherapy and radiation therapy, which directly target cancer cells, immunotherapy stimulates the immune system to recognize and attack cancer cells. Cancer immunotherapy drugs are intended to alter or boost the body's natural immune response in order to fight cancer. This market is research-driven, with a strong reliance on the discovery of molecules capable of generating an immune response against a wide range of indications. The North America cancer immunotherapy market is primarily driven by an increase in cancer cases, rising demand for personalized medicine, biotechnology advancements, and a better understanding of immune checkpoint mechanisms. Additionally, favorable government initiatives, extensive R&D activities, and collaborations among pharmaceutical companies help to drive market growth. Also, the introduction of novel immunotherapeutic agents such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, as well as the expansion of applications across various cancer types, are boosting the market.
 

Report Coverage

This research report categorizes for the North America cancer immunotherapy market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the North America cancer immunotherapy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the North America cancer immunotherapy market.

Driving Factors

Traditional chemotherapy had disadvantages such as organ failure and cancer recurrence, which prompted patients to adopt new cancer immunotherapy. Also, technological advancements and the development of new drugs have fueled the expansion of the cancer immunotherapy market. Cancer immunotherapy directs the immune system to target and destroy cancerous cells. This therapy has fewer side effects and has long-term treatment effects, increasing demand for cancer immunotherapy around the world. Additionally, the unfortunate rise in cancer diagnoses has been a major driver of the North American cancer immunotherapy market. The incidence of various cancers is expected to rise as the population ages and risk factors such as smoking and obesity become more prevalent. This expands the patient pool looking for effective treatments, accelerating the adoption of immunotherapy, which has promising results and potentially fewer side effects than traditional therapies.

Restraining Factors

The high cost of cancer immunotherapy drugs is a major restraint on the growth of the North American market. These treatments can be costly for patients and healthcare systems. Furthermore, complex reimbursement policies and lengthy approval processes by insurance companies can create access barriers for patients, limiting market penetration.

Market Segmentation

The North America cancer immunotherapy market share is classified into type of therapy and distribution channel.

• The checkpoint inhibitors segment is expected to hold the largest market share through the forecast period.

The North America cancer immunotherapy market is segmented by type of therapy into checkpoint inhibitors, monoclonal antibodies, vaccines, cell therapies, immunomodulators, and oncolytic virus. Among these, the checkpoint inhibitors segment is expected to hold the largest market share through the forecast period. These inhibitors, which include drugs such as pembrolizumab and nivolumab, have received a lot of attention for their ability to boost the body's immune response against cancer cells by blocking specific checkpoints that inhibit immune system activity. With extensive research and development efforts and proven efficacy in various cancer types, checkpoint inhibitors are the leading segment, driving significant market growth and adoption among healthcare providers and patients across North America.

• The hospital pharmacy segment is expected to dominate the North America cancer immunotherapy market during the forecast period.       

Based on the distribution channel, the North America cancer immunotherapy market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. Among these, the hospital pharmacy segment is expected to dominate the North America cancer immunotherapy market during the forecast period. The dominance can be attributed to its accessibility, specialized oncology care, and advanced immunotherapeutic treatments. Hospitals frequently serve as primary sites for cancer diagnosis, treatment, and management, resulting in increased demand for immunotherapy drugs.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the North America cancer immunotherapy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Immatics and Moderna
• Pfizer Inc.
• AstraZeneca
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Novartis AG
• Lilly
• Johnson & Johnson Services, Inc.
• Bayer AG
• Astellas Pharma Inc.
• Gilead Sciences, Inc.
• GSK plc
• Sanofi
• AbbVie Inc.
• Atara Biotherapeutics, Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In September 2023, Immatics and Moderna strategically collaborated to create Oncology Therapeutics. The collaboration include an assessment of Immatics' investigational PRAME203 TCRT in combination with Moderna's MARTE mRNA cancer vaccine.

Market Segment

This study forecasts revenue at North America, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the North America cancer immunotherapy market based on the below-mentioned segments:

North America Cancer Immunotherapy Market, By Type of Therapy

• Checkpoint Inhibitors
• Monoclonal Antibodies
• Vaccines
• Cell Therapies
• Immunomodulators
• Oncolytic Virus

North America Cancer Immunotherapy Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy